A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).
E. Angevin
No relevant relationships to disclose
V. Grünwald
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Pfizer
A. Ravaud
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
D. E. Castellano
No relevant relationships to disclose
C. C. Lin
No relevant relationships to disclose
J. E. Gschwend
Consultant or Advisory Role - Novartis
Honoraria - Novartis
A. L. Harzstark
No relevant relationships to disclose
J. Chang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Y. Wang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
M. M. Shi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
B. J. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche